ArticleJournal for immunotherapy of cancer2021

FOXP3-based immune risk model for recurrence prediction in small-cell lung cancer at stages I-III.

Minlin Jiang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.